Vaccine Contract Manufacturing Market To Reach $3.60 Billion By 2030

Vaccine Contract Manufacturing Market Growth & Trends

The global vaccine contract manufacturing market size is expected to reach USD 3.60 billion by 2030 and it is projected to grow at a CAGR of 7.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is anticipated to witness the significant CAGR over the forecast period, thanks to rising demand for vaccine development from the private sector as well as governments in industrialized and developing countries.

Vaccine contract services offer cost-saving benefits to their clients. They also help save time in the operations and management of a production and research facility. These advantages associated with Contract Manufacturing Organizations (CMOs) are expected to benefit emerging players, start-ups, and small players who lack adequate facilities and resources required for vaccine development.

Vaccination coverage is increasing across the globe. According to data published by the Pan American Health Organization, in 2022, the regional coverage of DPT3 was 85%. 13 countries and territories attained a DPT3-containing vaccine coverage of 95%, while 14 others reported 80% coverage across all municipalities. In addition, 21 countries reported an improvement in their DPT3 coverage from 2021 to 2022.Moreover, according to WHO, the percentage of children receiving the initial dose of the measles vaccine rose from 81% in 2021 to 83% in 2022; however, this remains below the 2019 level of 86%. On a global scale, the coverage for the first dose of HPV in girls increased from 16% in 2021 to 21% in 2022.

Furthermore, key companies in the market are undertaking various strategic initiatives to expand their market presence and product reach. For instance, in June 2023, Lonza and Vertex Pharmaceuticals, Inc. announced a strategic partnership to scale up manufacturing and support commercial production of Vertex's T1D cell therapy portfolio. They planned to further co-invest to build a dedicated facility in Portsmouth, New Hampshire (U.S.). Moreover, in January 2023, Catalent, Inc. signed a development and license agreement with Ethicann Pharmaceuticals Inc. to develop Ethicann's clinical drug pipeline using Catalent's Zydis Orally Disintegrating Tablet (ODT) technology. This was aimed to ensure improved patient acceptance and convenience.

 Request a free sample copy or view report summary: Vaccine Contract Manufacturing Market Report

Vaccine Contract Manufacturing Market Report Highlights

• Contract services for the development of attenuated vaccines accounted for the major share in the market based on vaccine type. This can be attributed to the fact that these vaccines offer immunity for a lifetime with only one or two doses

• DNA vaccines form the fastest-growing segment by type, with several kinds already being tested on humans

• Based on workflow, downstream processing dominated the market mainly due to the necessity of mature and reliable biotechnology tools for product recovery. Various research initiatives in the space are also contributing to advancing downstream workflows

• Based on application, contract services for the development of human-use vaccines held the largest share owing to their high adoption to develop vaccines against influenza and other illnesses

• North America dominated the overall market with revenue share of over 33.58% in 2023. This can be attributed to the presence of a substantial number of vaccine contract manufacturers in the U.S. Presence of an effective regulatory framework for biologics, including vaccines

Vaccine Contract Manufacturing Market Segmentation

Grand View Research has segmented the global vaccine contract manufacturing market based on vaccine type, workflow, application, type, product type, phase, scale of operation, service type, end-use and region:

Vaccine Contract Manufacturing Type Outlook (Revenue, USD Million, 2018 - 2030)

• Attenuated

• Inactivated

• Subunit-based

• Toxoid-based

• DNA-based

Vaccine Contract Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)

• Downstream

• Fill & Finish Operations

• Analytical & QC Studies

• Packaging

• Upstream

• Mammalian Expression Systems

• Bacterial Expression Systems

• Yeast Expression Systems

• Baculovirus/Insect Expression Systems

• Others

Vaccine Contract Manufacturing Type Outlook (Revenue, USD Million, 2018 - 2030)

• Viral

• Bacterial

• Others

Vaccine Contract Manufacturing Product Type Outlook (Revenue, USD Million, 2018 - 2030)

• Single Vaccines

• Combination Vaccines

Vaccine Contract Manufacturing Phase Outlook (Revenue, USD Million, 2018 - 2030)

• Preclinical

• Clinical

• Commercial

Vaccine Contract Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)

• Human Use

• Veterinary

Vaccine Contract Manufacturing Scale of Operation Outlook (Revenue, USD Million, 2018 - 2030)

• Small Scale

• Medium Scale

• Large Scale

Vaccine Contract Manufacturing Service Type Outlook (Revenue, USD Million, 2018 - 2030)

• Fill-Finish

• Bulk Products

Vaccine Contract Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Biopharmaceutical Companies

• Research Academies & Government Institutes

Vaccine Contract Manufacturing Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Vaccine Contract Manufacturing Market

• Lonza

• FUJIFILM Diosynth Biotechnologies

• Ajinomoto Co., Inc.

• Merck KGaA

• Catalent, Inc

• IDT Biologika GmbH

• Curia Global, Inc.

• ICON plc.

• Cytovance Biologics (Hepalink)

• Syngene International Limited